Skip to main content

Q1 review: Strong IT & telecom show, growing market share of private banks indicate big becoming bigger

IT has emerged as the clear winner coming out almost unhurt from the lockdown.

 

Q1 results indicate clear trends for investors

After the sharp bounce back from March lows, stock markets globally are in a high-valuation zone. Nifty at 11,000 is trading at a trailing PE of around 26, which under normal conditions would be described as bubble valuation.

But these are not normal times as unprecedented liquidity and historically low-interest rates can support high valuations, but a reversion to mean is inevitable and therefore investors should focus on earnings support to valuations. Do the earnings, present and potential, support the valuations?

Let’s take cues from the Q1 results:

IT is the clear winner

IT has emerged as the clear winner coming out almost unhurt from the lockdown. With work-from-home at more than 95 percent, all the big boys gained from robust demand from clients.

The move to cloud and automation has gathered momentum in the COVID-struck world. Even though all IT majors have done well, Infosys has broken out from the herd with a clear beat over market estimates on revenue and profits.

Second rung IT companies also have shown similar positive trends. The market has been quick to discount the standout performance with the IT index gaining a whopping 22 percent in July. IT is likely to remain resilient, going forward.

Telecom is riding the lockdown wave

The sector that converted the crisis into opportunity is telecom. Aided by increasing work-from-home (WFH) and exploding data consumption, telecom is riding the COVID-19 wave. Since telecom is now a near duopoly market, Reliance Industries and Bharti Airtel are the clear winners.

RIL stands out with a smart 7 percent spurt in ARPUs. With WFH becoming the new normal for many businesses like IT, the prospects for the sector are, indeed, bright.

Darwinism in the market: Fittest will survive and grow

A clear trend in these turbulent and disruptive times is 'the big growing bigger and better'. Large private companies/market leaders are gaining market share at the expense of weaker players.

A good example is HDFC Bank, which has reported 20.9 percent increase in deposits and 24.6 percent increase in loan disbursements in Q1. PSU banks constrained by capital adequacy are clear laggards. Midcap banking stocks are struggling. The phenomenon of big growing bigger is clearly pronounced in segments like telecom, FMCG, paints, banking and NBFCs.

Cement industry surprised both on price and volume front

Cement industry has surprised with smart improvement in price and volume. Robust rural demand has helped the industry substantially. Even though most companies have reported good numbers, the largecap UltraTech has come out with strong numbers beating the street.

Pharma, healing the sick, benefits from the pandemic

Pharma index, up by 13 percent in July alone, is a winner in COVID-19 times. Most companies, large and small, have reported good numbers. Aurobindo Pharma stock, surging 180 percent from the March lows, stole the show in an impressive performance by the industry.

FMCG in slowdown mode

Even though FMCG has done reasonably well with people stocking up during the lockdown, demand is likely to remain subdued, going forward. Q1 results of Britannia and Nestle stood out in the segment. However, a contracting economy, rising unemployment and falling incomes do not bode well for the sector in FY21.

Autos, after the sudden brake, is slowly accelerating

Maruti's first quarterly loss since 2001 is a reflection of the pain inflicted by the lockdown on the auto industry. But the prospects of the car industry and 2-wheelers are set to improve aided by the increasing preference for private mobility. Q2 numbers will provide evidence of this trend and the market is already discounting this.


Though many results are yet to come, the main takeaways are the stellar performance of IT, the robust show of telecom, the growing market share of private sector banks and, broadly, the phenomenon of the big becoming bigger.

The author is Chief Investment Strategist at Geojit Financial Services.

Source - Moneycontrol.com

 


Comments

Popular posts from this blog

Panacea Biotech shares hit 5% upper circuit after dengue vaccine completes phase I & II study

DengiAIl induced robust neutralising antibody responses against all the four dengue virus serotypes, the company has said in an exchange filing. Panacea Biotech share price hit 5 percent upper circuit on the BSE on September 24 after the company completed phases I and II study of its dengue vaccine candidate DengiAIl. "Panacea Biotec Ltd. is delighted to announce the successful completion of its Phase I/II study to evaluate the safety and immunogenicity of its vaccine, DengiAll, a single-dose liveattenuated tetravalent vaccine," the company said in an exchange filing. Live-attenuated vaccines contain weakened bacteria or viruses that trigger an immune response but do not cause disease. The company said DengiAIl induced robust neutralising antibody responses against all the four dengue virus serotypes. DengiAIl has been found to be safe and well-tolerated with no serious adverse effects, the company said. After a single-dose, more than 80 percent of the participants ...

Brokerages place bets on Titan, see double-digit upside in the stock

Titan can get benefits from the strong market share in the jewellery and wrist watches segment, mainly driven by a wide range of product portfolio catering mainly to the premium and value-added designer jewellery segment. After three consecutive sessions of losses, shares of Titan Company rose over a percent in morning trade on BSE on September 23. The company was dealt a severe blow by COVID-19 as the pandemic triggered strict lockdowns completely battered the retail sector. In the calendar year so far, shares of this one of the largest, most efficient and profitable specialty retailer in India are 7 percent down. The company reported a net standalone loss of Rs 270 crore for the quarter ended June 2020 as the COVID-19 pandemic hit business. The loss was higher than a CNBC-TV18 poll estimate of Rs 175 crore. Standalone revenue during the quarter declined 62.3 percent year-on-year to Rs 1,862 crore compared to the corresponding period last fiscal. Light at the end ...

Check Chemcon Speciality Chemicals IPO allotment status in four simple steps

Equity shares will get credited into the accounts of eligible investors by September 30 and the listing of equity shares will be on October 1, 2020. Chemcon Speciality Chemicals, the manufacturer for pharmaceutical and oilfields industries, is expected to announce the basis of allotment early next week. As per the schedule provided by the company, the finalisation of the basis of the allotment will be done by September 28 and the initiation of refunds or unblocking of funds from ASBA account will take place on September 29. Equity shares will get credited to the accounts of eligible investors by September 30 and the listing will be on October The IPO comprised a fresh issue of Rs 165 crore and an offer for sale of Rs 153 crore by promoters. The company will utilise fresh issue proceeds for expansion of manufacturing facility, working capital requirements, and general corporate purposes. Chemcon manufactures specialised chemicals, such as Hexamethyldisilazane (HMDS) and Chloromethyl Iso...